Galectin Therapeutics Incorporated (NASDAQ:GALT) Shorted Shares Increased 18.01% After Market Selling

January 19, 2018 - By Peter Erickson

 Galectin Therapeutics Incorporated (NASDAQ:GALT) Shorted Shares Increased 18.01% After Market Selling

Investors sentiment decreased to 0.67 in 2017 Q3. Its down 1.22, from 1.89 in 2017Q2. It is negative, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported.
Buckingham Asset Ltd Limited Liability Company invested in 0.03% or 50,000 shares. Illinois-based Guggenheim Lc has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). 54,600 were accumulated by Cutter And Comm Brokerage Inc. Goldman Sachs Group Inc has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Schwab Charles Inv owns 21,400 shares for 0% of their portfolio. Vanguard Group Inc Inc invested in 0% or 850,948 shares. Wells Fargo & Mn, a California-based fund reported 11,882 shares. Morgan Stanley owns 103,436 shares. Us Fincl Bank De has 118,921 shares. Tci Wealth Advsr has invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). 15,721 were accumulated by Cetera Advisor Netwr Ltd Liability Corporation. Next Fincl Group owns 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 1,000 shares. Northern Tru Corporation accumulated 80,739 shares or 0% of the stock. Royal Fincl Bank Of Canada invested in 0% or 26 shares. California Employees Retirement Systems invested in 23,450 shares or 0% of the stock.

The stock of Galectin Therapeutics Incorporated (NASDAQ:GALT) registered an increase of 18.01% in short interest. GALT’s total short interest was 1.29 million shares in January as published by FINRA. Its up 18.01% from 1.09M shares, reported previously. With 334,200 shares average volume, it will take short sellers 4 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Incorporated’s float is 5.15%.

The stock decreased 3.96% or $0.23 during the last trading session, reaching $5.58. About 545,569 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since January 19, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $201.65 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The rating was downgraded by FBR Capital on Monday, October 3 to “Mkt Perform”. H.C. Wainwright downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) on Thursday, September 29 to “Neutral” rating. H.C. Wainwright upgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) on Thursday, March 30 to “Buy” rating. TH Capital downgraded the shares of GALT in report on Wednesday, September 28 to “Sell” rating. Roth Capital downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) on Wednesday, September 28 to “Sell” rating. The rating was maintained by Roth Capital with “Buy” on Thursday, December 7. The rating was initiated by H.C. Wainwright with “Buy” on Monday, September 21. As per Wednesday, June 14, the company rating was maintained by H.C. Wainwright. Roth Capital maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) on Thursday, January 4 with “Buy” rating. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) has “Buy” rating given on Monday, March 28 by H.C. Wainwright.

More recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Zacks.com which released: “Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1% December 28, 2017” on December 28, 2017. Also Seekingalpha.com published the news titled: “Galectin Therapeutics Is On To Something Big” on January 07, 2018. Prnewswire.com‘s news article titled: “Technical Perspectives on Generic Drugs Stocks — Fibrocell Science, Galectin …” with publication date: January 19, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.